FSS intend to initiate stakeholder engagement during the 2024 – 25 business year, and will seek early opportunities to gather initial views on braille labelling from relevant business stakeholders where practical.

Table 1 provides information on total number of inpatient, daycase and outpatient hospital episodes where a cataract surgery procedure was recorded, at the Princess Alexandra Eye Pavilion by financial year from 2004-05. It is not possible to provide figures for 1999-2003, as prior to 2004 activity at the Princess Alexandra Eye Pavilion was recorded under the Royal Infirmary of Edinburgh along with activity from other facilities on the Lauriston Place site.

Table 1: Number of Cataract eye surgery procedures at the Princess Alexandra Eye Pavilion, 2004-05 to 2022-23

Table 1 provides information on total number of inpatient, daycase and outpatient hospital episodes where an emergency eye surgery procedure was recorded, at the Princess Alexandra Eye Pavilion by financial year from 2004-05. It is not possible to provide figures for 1999-2003, as prior to 2004 activity at the Princess Alexandra Eye Pavilion was recorded under the Royal Infirmary of Edinburgh along with activity from other facilities on the Lauriston Place site.

Table 1: Number of emergency Eye procedures at the Princess Alexandra Eye Pavilion, 2004-05 to 2022-23

FSS officials meet with officials in the Department for Environment, Food and Rural Affairs (Defra) and the Food Standards Agency (FSA) in Wales and Northern Ireland, lead departments for food labelling in the rest of the UK, on a bimonthly basis. FSS continues to highlight that braille labelling of food products is being considered by the Scottish Parliament Citizen Participation and Public Petitions Committee, and the importance being placed on this issue in Scotland. Development of any policy proposals would need to be considered on a four-nation basis under the UK Food Compositional Standards and Labelling Common Framework.

The Draft Scottish Budget 2024-25 was published on 19 Dec 2023.

The Bill is currently at ‘Stage 2 – Changes to Detail’ with any amendments to be considered at a meeting on 20 February 2024.

Once moved to ‘Stage 3 – Final amendments and vote’ a further vote will confirm that the Bill will become an Act before April 2024.

No impact assessments have been conducted as the Scottish Government’s position is and remains that the charitable status of any organisation is a matter for OSCR. Whether independent fee-charging schools meet the charity test is a matter for OSCR who operate independently of the Scottish Government.

Any changes to the way OSCR determine charitable status would need to be made by primary legislation, following thorough consultation, impact assessments and analysis.

The Civil Contingencies Act 2004 (CCA) and the Civil Contingencies Act 2004 (Contingency Planning) (Scotland) Regulations 2005 is the legislation which outlines the categorised responders, and their duty to prepare for civil emergencies within Scotland.

The CCA divides responders into two categories, category 1 and category 2, with local authorities included as a category 1 responder. The CCA imposes a set of duties on each category of responders, but it does not confer any powers upon the categorised responders.

The UK Government has a legal obligation to review the CCA every 5 years. The most recent review was published in 2022 and the report, including the findings and recommendations, can be viewed here - Civil Contingencies Act 2004: post implementation review report (2022) - GOV.UK (www.gov.uk) .

The Scottish Government does not currently have any plans to review the accompanying regulations to the CCA.

The most recent surveillance report from Public Health Scotland (PHS) indicates that the number of people tested for HCV antibody in Scotland in 2022 had almost recovered to the level seen before the pandemic in 2019, however we know that further work is required to reach undiagnosed individuals living with HCV.

Current work includes ensuring that opt-out testing is proactively and consistently offered in key settings such as drug services and prisons, and we are also working with three Health Boards to pilot opt-out testing for HCV and other blood borne viruses (BBVs) in emergency department settings.

The Scottish Government has also funded research to identify the optimal approach to testing for BBVs for people at highest risk in Scotland, in order to reduce undiagnosed infections, increase linkage to care for those not in treatment, improve health and prevent BBV transmission. The findings will inform future testing strategies.

The Scottish Government remains committed to achieving the elimination of hepatitis C (HCV) in Scotland by the end of the 2024-25 financial year. However, we know that achieving elimination and meeting our target will take a concerted effort at national and local level.

As outlined in the Scottish Government’s recently published Sexual Health and Blood Borne Virus (SHBBV) Action Plan 2023-26 , we will be reinstating SHBBV-focused visits to NHS Boards. This is part of our ongoing work to support boards on a case-by-case basis to understand their unique circumstances and help overcome barriers they may face to achieving HCV elimination and other SHBBV goals. We will also continue to work with the Hepatitis C Elimination Implementation Group to consider where support is most required.

Progress towards eliminating hepatitis C (HCV) as a public health concern is monitored by Public Health Scotland (PHS) with the most recent surveillance report in December 2023 indicating that major progress continues to be made on a number of HCV elimination targets in Scotland. For example, 86% of those previously diagnosed have been treated for their infection (in excess of the World Health Organization target of 80%).

A key indicator of progress toward HCV elimination is prevalence of chronic HCV among people who inject drugs (PWID) which is monitored via the Needle Exchange Surveillance Initiative survey led by Glasgow Caledonian University in association with PHS. This found the prevalence of chronic HCV infection among PWID in Scotland had reduced by approximately 50%, from 37% in 2015-16 to 19% in 2019-2020. Results for the latest NESI survey conducted during 2022-23 are expected to be published in mid 2024-25.

Treatment targets are currently published at Scotland level only, however a new PHS-led blood borne virus and sexually transmitted infection dashboard is scheduled for launch in 2024-25 which will include data on HCV treatment (alongside other indicators) and will help to monitor progress on elimination at NHS board level.